ArticleBMC pediatrics2026
Base deficit and alactic base excess are promising early biological markers in pediatric sepsis.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe diagnosis and management of pediatric sepsis remain challenging and time-sensitive. Early biological markers that may identify patients at risk of progression to septic shock are needed. Base deficit (BD) has been associated with adverse outcomes in adult sepsis, while alactic base excess (ABE) reflects non-lactate metabolic acidosis. This study aimed to evaluate the performance of BD and ABE compared with lactate in pediatric sepsis and to assess their association with time to progression to septic shock.
methodsThis retrospective single-center cohort study included pediatric patients with sepsis between January 1, 2020, and September 1, 2024. Biomarkers were obtained at initial presentation prior to resuscitation. BD and ABE were categorized into normal, abnormal, and extremely abnormal groups based on distribution thresholds, while lactate was classified as normal (≤2.2 mmol/L) or abnormal (>2.2 mmol/L). Diagnostic performance was assessed using ROC curve analysis. Time-to-event analyses were performed using Kaplan-Meier curves and multivariable Cox regression models adjusted for BMI, CRP, albumin, and Phoenix Sepsis Score.
resultsA total of 44 patients were included, of whom 30 (68.18%) developed septic shock. Lactate demonstrated lower discriminative performance (AUC 0.624, 95% CI 0.447-0.800) compared with BD (AUC 0.940, 95% CI 0.875-0.999) and ABE (AUC 0.905, 95% CI 0.813-0.997). Both BD and ABE showed higher sensitivity and specificity for identifying patients who progressed to septic shock. In adjusted analyses, abnormal and extremely abnormal ABE and BD were associated with an increased hazard of progression to septic shock. Median time to shock was shortest in patients with extremely abnormal BD and ABE (approximately 8-9 hours), followed by abnormal lactate (13 hours), abnormal ABE (17 hours), and abnormal BD (18 hours).
conclusionsBD and ABE were associated with progression to septic shock in pediatric sepsis and may provide clinically relevant information for early risk stratification. In this cohort, these markers demonstrated stronger discriminative performance than lactate and may reflect metabolic disturbances present earlier in the disease course. However, these findings should be interpreted cautiously given the retrospective design and require prospective multicenter validation before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.